Drugs / vilastobart
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04896697 | Sep 2021 → May 2026 | — | Xilio Development, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vilastobart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04896697 ↗ |
| Action | Inhibit | “XTX101 retains the full potency of an Fc-enhanced CTLA-4 antagonist within the TME” PMID 38164757 ↗ Dec 2023 |
| Modality | Monoclonal antibody | — CHEMBL5314894 ↗ |